Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients

Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of highly active relapsing-remitting multiple sclerosis (MS). The principal adverse effect is the development of secondary autoimmune disorders during the immune reconstitution period after alemtuzumab, with autoim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Kazakou, Paraskevi, Tzanetakos, Dimitrios, Vakrakou, Aigli G, Tzartos, John S, Anagnostouli, Maria, Koutsis, Georgios, Andreadou, Elisabeth, Evangelopoulos, Maria Eleptheria, Kilidireas, Constantinos, Zapanti, Evangelia
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Thyroid
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089514/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1727
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados